ダラツムマブ
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230744/.
↑ “ASCO: Drug Shows Promise in Myeloma”. MedPage Today. http://www.medpagetoday.com/HematologyOncology/Myeloma/33115
↑ “Daratumumab Continues To Show Promise For Relapsed/Refractory Myeloma Patients (ASH 2012)”. The Myeloma Beacon. http://www.myelomabeacon.com/news/2013/01/09/daratumumab-for-relapsed-refractory-myeloma-patients-ash-2012/ 2013年1月31日閲覧。
↑ “Daratumumab, lenalidomide, and dexamethasone for multiple myeloma”. New England Journal of Medicine 375 (14): 1319–1331. (2016). doi:10.1056/NEJMoa1607751. PMID 27705267.
↑ “Daratumumab, bortezomib, and dexamethasone for multiple myeloma”. New England Journal of Medicine 375 (8): 754–766. (2016). doi:10.1056/NEJMoa1606038.